HHS sponsors development of drug for hospitalized influenza patients

29 September 2015

Development of an experimental influenza antiviral drug that may be more potent and could have a longer treatment window than existing drugs will receive support from the US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR). The drug is being developed for use in treating patients hospitalized with influenza.

If development is successful and the drug receives US Food and Drug Administration approval, the drug could become the first specifically for this use and potentially the first in a new class of influenza antivirals.

$103.5 million contract with Janssen Pharma

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical